SIC 2834 – Pharmaceutical Preparations
Valuation | |
---|---|
Market Cap ($M) | 112.59 |
Enterprise Value ($M) | 95.70 |
Book Value ($M) | 25.99 |
Book Value / Share | 2.08 |
Price / Book | 4.33 |
NCAV ($M) | 3.34 |
NCAV / Share | 0.27 |
Price / NCAV | 33.73 |
Profitability (mra) | |
---|---|
Return on Invested Capital (ROIC) | 0.07 |
Return on Assets (ROA) | 0.04 |
Return on Equity (ROE) | 0.08 |
Liquidity (mrq) | |
---|---|
Quick Ratio | 1.01 |
Current Ratio | 1.69 |
Balance Sheet (mrq) ($M) | |
---|---|
Current Assets | 37.65 |
Assets | 60.30 |
Liabilities | 34.31 |
Debt | n/a |
Equity | n/a |
Income Statement (mra) ($M) | |
---|---|
Revenue | 200.16 |
Operating Income | 4.33 |
Net Income | 2.94 |
Earnings Per Share Diluted | n/a |
Earnings Per Share Basic | n/a |
Cash Flow Statement (mra) ($M) | |
---|---|
Cash From Operations | 12.20 |
Cash from Investing | -2.25 |
Cash from Financing | -14.42 |
(click for more detail) |
File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
---|---|---|---|---|
13D/A | Radoff Bradley Louis | 4.99 | -26.39 | |
13D/A | Sudbury Capital Management, LLC | 5.90 | 0.00 | |
13G/A | Renaissance Technologies Llc | 6.51 | -2.40 | |
13D/A | Sudbury Capital Fund, LP | 5.80 | 16.05 |
Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
---|---|---|---|---|
(click for more detail) |
Date | Insider Trades | Code | Shares | Value |
---|---|---|---|---|
(click for more detail) |
Short Volume | |||
---|---|---|---|
Market Date | Short Volume | Total Volume | Short Volume Ratio |
72,072 | 312,823 | 23.04 | |
16,403 | 100,882 | 16.26 | |
34,491 | 92,885 | 37.13 | |
25,687 | 103,575 | 24.80 | |
(click for more detail) |
Similar Companies | |
---|---|
KTTA – Pasithea Therapeutics Corp. | KZR – Kezar Life Sciences, Inc. |
LEXX – Lexaria Bioscience Corp. | LGVN – Longeveron Inc. |
LIPO – Lipella Pharmaceuticals Inc. |
Financial data and stock pages provided by
Fintel.io